Newsroom


Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.
07

Media Contacts:
Kristy Marks
kristy.marks@bausch.com
(908) 927-0683

Don Murphy
don.murphy@zenogroup.com
(212) 299-8970



BAUSCH + LOMB ANNOUNCES THE U.S. LAUNCH OF LUMIFY, THE FIRST AND ONLY OTC REDNESS RELIEVING EYE DROP WITH LOW-DOSE BRIMONIDINE


Backed by Clinical Trials, LUMIFY Demonstrates a Strong Safety Profile with Fast-Acting and
Long-Lasting Efficacy



BRIDGEWATER, N.J., May 7, 2018 – Bausch + Lomb, a leading global eye health company, today announced the launch of LUMIFY™ (brimonidine tartrate ophthalmic solution 0.025%), the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate for the treatment of eye redness. In clinical trials, LUMIFY eye drops demonstrated a strong safety and efficacy profile with low risk for rebound redness and 95% symptom improvement seen at one minute and lasting up to eight hours.

"We are excited to make LUMIFY available to the millions of patients who may benefit from fast acting and long lasting redness reduction with a low risk of potential side effects associated with other redness relievers,” said Joseph Gordon, president, Consumer Healthcare and Vision Care, Bausch + Lomb. “We’re proud to provide these innovative eye drops to eye care professionals and their patients who have been looking for a new redness relieving alternative.” 

LUMIFY is an alpha-2 (α2)-adrenergic receptor (AR) agonist with a unique method of action that selectively constricts venules, while maintaining the availability of oxygen to surrounding tissue. Other redness relievers on the market today are α1- or mixed α1-/α2-AR agonists that constrict the arterioles and venules, and may deprive the eye of oxygen resulting in an increased potential for rebound redness and tachyphylaxis. 

Six clinical studies were conducted in over 600 patients to evaluate the safety and efficacy of LUMIFY, including studies with both pediatric and geriatric subjects. The strong efficacy and safety profile of LUMIFY includes not only significant redness reduction for up to eight hours, but a low risk of allergic reactions among all patient groups.  

“LUMIFY eye drops deliver a safe and effective redness relieving OTC option that my patients have been asking for,” said Paul Karpecki, O.D., FAAO, director of Corneal Services at Kentucky Eye Institute. “I am excited to introduce this unique new option into my practice and offer my patients long-lasting symptom relief without the adverse effects commonly associated with other redness relievers.”

LUMIFY is available for purchase at major retailers nationwide, including Walgreens, CVS, Rite Aid, Walmart, Target and Amazon. The bottles, available in 2.5 mL and 7.5 mL sizes, have suggested retail prices of $14.99 and $25.99, respectively. 

The brimonidine tartrate ophthalmic solution 0.025% product was licensed by Eye Therapies, Inc. to Bausch & Lomb Incorporated or its affiliates.

For more information, please visit www.LumifyEyeDrops.com/professional

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people's eyesight. Its core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in our industry, which is available in more than 100 countries. 

###

LUMIFY is a trademark of Bausch & Lomb Incorporated or its affiliates.
© 2018 Bausch & Lomb Incorporated. 
LUM.0177.USA.18

Actions: E-mail | Permalink |